Rivian pauses plans to make electric vans in Europe with Mercedes-Benz

Rivian pauses plans to make electric vans in Europe with Mercedes-Benz


Rivian said Monday it was pausing plans to manufacture electric commercial vans in Europe and would “no longer pursue” the agreement it made with Mercedes-Benz just three months ago.

“We’ve decided to pause discussions with Mercedes-Benz Vans regarding the Memorandum of Understanding we signed earlier this year for joint production of electric vans in Europe,” Rivian CEO RJ Scaringe said, noting the company was pursuing “the best risk-adjusted returns” on its capital investments.

“At this point in time, we believe focusing on our consumer business, as well as our existing commercial business, represent the most attractive near-term opportunities to maximize value for Rivian,” he added.

The company said it remains open to exploring future work with Mercedes-Benz “at a more appropriate time for Rivian.” The companies signed their original memorandum of understanding in September.

Mercedes-Benz said Rivian’s decision would not impact the timeline of its electrification strategy or the planned ramp-up of its new electric vehicle manufacturing site in Jawor, Poland.

This is a breaking news story and will be updated shortly.



Source

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored
Business

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored

In this photo illustration Hantavirus samples are seen in Ankara, Turkiye on May 6, 2026. Arman Onal | Anadolu | Getty Images The U.S. Centers for Disease Control and Prevention said there are no hantavirus cases in the country as of Thursday, as it monitors 41 people for the virus. The agency said the risk […]

Read More
These three artworks could sell for 0 million each next week as May auctions begin
Business

These three artworks could sell for $100 million each next week as May auctions begin

A large-scale Jackson Pollock drip painting titled, “Number 7A, 1948.” Crystal Lau | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Nearly $2 billion worth of art will come up […]

Read More
Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data
Business

Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. […]

Read More